- Recruiting
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
Updated: May 26, 2022
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04184050
Official Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
First Posted : December 3, 2019
Click here to see details on ClinicalTrials.gov
Drug: HPN217
BCMA/CD3e Tri-specific T-cell Activating Construct HPN217
BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 (Code C171631)
Anti-BCMA/CD3e TriTAC HPN217
BCMA/CD3 Tri-specific T-cell Activating Construct HPN217
BCMA/CD3e Tri-specific T-cell Activating Construct HPN217
BCMA/CD3e TriTAC HPN217